Compare Natera Inc. Common Stock (NTRA) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs S&P Global Inc — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while S&P Global Inc trades at $410.98 (market cap $120.87B). The key difference: S&P Global Inc is far larger — about 2.1× Natera Inc. Common Stock's market cap, and S&P Global Inc pays a 0.95% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and S&P Global Inc for 124 Days on average.
| NTRA | SPGI | |
|---|---|---|
Market Cap | $57.03B | $120.87B |
Volume | 1,131,157 | 1,391,754 |
Sector | Health | Financials |
52-Week High | $425.64 | $517.92 |
52-Week Low | $179.42 | $370.42 |
Typical Hold Time | 0 Days | 124 Days |
Enterprise Value | $56.18B | $132.35B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
S&P Global (SPGI) trades at $408.57, down 0.88% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong fundamentals with Q1 and Q2 2026 earnings beats, revenue growth to $15.34B in 2025, and robust profitability margins. Recent news highlights expansion into digital asset risk assessment and AI-driven growth initiatives.
Outlook remains positive with an 85.7% analyst buy rating and a $509.50 consensus price target, implying significant upside. Key risks include execution of acquisitions and macroeconomic sensitivity, but the firm's entrenched market position and cash flow stability support a favorable investment case for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
